Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Peer-Reviewed Evidence
HomeDrug RegistryCompareKETOROLAC TROMETHAMINE vs ACETAMINOPHEN AND IBUPROFEN
Comparative Pharmacology

KETOROLAC TROMETHAMINE vs ACETAMINOPHEN AND IBUPROFEN Comparison

Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.

Clinical EssentialsPharmacokineticsSpecial PopulationsSafety & MonitoringPregnancy & Lactation
Differential Analysis

KETOROLAC TROMETHAMINE vs ACETAMINOPHEN AND IBUPROFEN

Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.

View KETOROLAC TROMETHAMINE Monograph View ACETAMINOPHEN AND IBUPROFEN Monograph
Clinical Insights
KETOROLAC TROMETHAMINE
NSAID
Category D/X
ACETAMINOPHEN AND IBUPROFEN
NSAID
Category D/X
TL;DR — Key Differences
  • Half-life: KETOROLAC TROMETHAMINE has a half-life of Terminal half-life is 5-6 hours in young adults, prolonged to 9-10 hours in elderly patients (≥65 years) and up to 12-15 hours in renal impairment (Cr Cl <30 m L/min). Context: q6h dosing interval recommended; accumulation risk in elderly/renal impairment.; ACETAMINOPHEN AND IBUPROFEN has Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment..
  • No direct drug-drug interaction has been documented between KETOROLAC TROMETHAMINE and ACETAMINOPHEN AND IBUPROFEN.
  • Pregnancy: KETOROLAC TROMETHAMINE is rated Category D/X; ACETAMINOPHEN AND IBUPROFEN is rated Category D/X.

Last clinically reviewed: June 2026 · OpiCalc Medical Review Team

Clinical Essentials

KETOROLAC TROMETHAMINE
ACETAMINOPHEN AND IBUPROFEN
Mechanism of Action
KETOROLAC TROMETHAMINE

Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing pain and inflammation.

ACETAMINOPHEN AND IBUPROFEN

Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.

Indications
KETOROLAC TROMETHAMINE

Short-term (≤5 days) management of moderately severe acute pain requiring analgesia at the opioid level,Moderate to severe acute pain, including postsurgical pain (FDA approved for parenteral and ophthalmic use),Ophthalmic: Prevention and reduction of inflammation and pain following cataract extraction and corneal refractive surgery

ACETAMINOPHEN AND IBUPROFEN

Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea

Standard Dosing
KETOROLAC TROMETHAMINE

10 mg orally every 4-6 hours, not to exceed 40 mg per day; or 15-30 mg intramuscularly or intravenously every 6 hours, not to exceed 120 mg per day (maximum 60 mg for single dose).

ACETAMINOPHEN AND IBUPROFEN

Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.

Direct Interaction
KETOROLAC TROMETHAMINE
No Direct Interaction
ACETAMINOPHEN AND IBUPROFEN
No Direct Interaction

Pharmacokinetics

KETOROLAC TROMETHAMINE
ACETAMINOPHEN AND IBUPROFEN
Half-Life
KETOROLAC TROMETHAMINE

Terminal half-life is 5-6 hours in young adults, prolonged to 9-10 hours in elderly patients (≥65 years) and up to 12-15 hours in renal impairment (Cr Cl <30 m L/min). Context: q6h dosing interval recommended; accumulation risk in elderly/renal impairment.

ACETAMINOPHEN AND IBUPROFEN

Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.

Metabolism
KETOROLAC TROMETHAMINE

Special Populations

KETOROLAC TROMETHAMINE
ACETAMINOPHEN AND IBUPROFEN
Renal Adjustments
KETOROLAC TROMETHAMINE

Contraindicated in patients with advanced renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-60 m L/min: reduce dose by 50% and limit to 60 mg/day IM/IV or 20 mg/day oral. No adjustment for mild impairment.

ACETAMINOPHEN AND IBUPROFEN

GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.

Hepatic Adjustments
KETOROLAC TROMETHAMINE

Safety & Monitoring

KETOROLAC TROMETHAMINE
ACETAMINOPHEN AND IBUPROFEN
Black Box Warnings
KETOROLAC TROMETHAMINE
FDA Black Box Warning

Cardiovascular risk: NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft (CABG) surgery. Gastrointestinal risk: NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning symptoms. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at greater risk.

Pregnancy & Lactation

KETOROLAC TROMETHAMINE
ACETAMINOPHEN AND IBUPROFEN
Teratogenic Risk
KETOROLAC TROMETHAMINE

Pregnancy Category C in first and second trimesters, Category D in third trimester and near term. Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. First trimester: limited human data, animal studies show adverse effects. Second trimester: use only if clearly needed; may cause fetal renal impairment.

ACETAMINOPHEN AND IBUPROFEN

First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.

Clinical Insights

KETOROLAC TROMETHAMINE
ACETAMINOPHEN AND IBUPROFEN
Clinical Pearls
KETOROLAC TROMETHAMINE

Ketorolac is a potent NSAID for short-term management of moderate to severe acute pain, not to exceed 5 days due to increased risk of GI bleeding, renal impairment, and cardiovascular events. Contraindicated in patients with active peptic ulcer disease, recent GI bleeding, advanced renal impairment, or at risk for bleeding (e.g., concurrent anticoagulants). Administer with food to reduce GI irritation; avoid use in patients with aspirin-sensitive asthma. Monitor renal function, liver enzymes, and signs of bleeding. Intramuscular injection should be given deeply and slowly; IV bolus over at least 15 seconds. Use lowest effective dose for shortest duration; not for minor or chronic pain. Not recommended for pediatric patients or during labor/delivery.

ACETAMINOPHEN AND IBUPROFEN

Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.

Safety Verification

Known Interactions

KETOROLAC TROMETHAMINE Risks

No interactions on record

ACETAMINOPHEN AND IBUPROFEN Risks

No interactions on record

Clinical Q&A

Frequently Asked Questions

Common clinical questions about KETOROLAC TROMETHAMINE vs ACETAMINOPHEN AND IBUPROFEN, answered by our medical review team.

1. What is the main difference between KETOROLAC TROMETHAMINE and ACETAMINOPHEN AND IBUPROFEN?

KETOROLAC TROMETHAMINE is a NSAID that works by Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing pain and inflammation.. ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.

2. Which is stronger: KETOROLAC TROMETHAMINE or ACETAMINOPHEN AND IBUPROFEN?

Potency comparisons between KETOROLAC TROMETHAMINE and ACETAMINOPHEN AND IBUPROFEN depend on the specific clinical indication. These are both NSAID agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.

3. What is the standard dosing for KETOROLAC TROMETHAMINE vs ACETAMINOPHEN AND IBUPROFEN?

The standard adult dose of KETOROLAC TROMETHAMINE is: 10 mg orally every 4-6 hours, not to exceed 40 mg per day; or 15-30 mg intramuscularly or intravenously every 6 hours, not to exceed 120 mg per day (maximum 60 mg for single dose).. The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.

4. Can you take KETOROLAC TROMETHAMINE and ACETAMINOPHEN AND IBUPROFEN together?

No direct drug-drug interaction has been formally documented between KETOROLAC TROMETHAMINE and ACETAMINOPHEN AND IBUPROFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.

5. Are KETOROLAC TROMETHAMINE and ACETAMINOPHEN AND IBUPROFEN safe during pregnancy?

The maternal-fetal safety profiles differ. KETOROLAC TROMETHAMINE is classified as Category D/X. Pregnancy Category C in first and second trimesters, Category D in third trimester and near term. Avoid in third trimester due to risk of premature closure of ductus arteriosus and. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.

Hepatic metabolism via conjugation (glucuronidation) and hydroxylation (involves CYP450 enzymes, primarily CYP2C9). Renal excretion of metabolites and unchanged drug (approximately 90% as glucuronide conjugates).

ACETAMINOPHEN AND IBUPROFEN

Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.

Excretion
KETOROLAC TROMETHAMINE

Primarily renal excretion: ~92% of dose excreted in urine as parent drug (60%) and metabolites (p-hydroxyketorolac, conjugated forms). Fecal excretion accounts for ~6%. Biliary excretion is minimal.

ACETAMINOPHEN AND IBUPROFEN

Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.

Protein Binding
KETOROLAC TROMETHAMINE

99% bound to plasma albumin. High binding limits distribution and may be affected by hypoalbuminemia.

ACETAMINOPHEN AND IBUPROFEN

Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).

VD (L/kg)
KETOROLAC TROMETHAMINE

0.15-0.3 L/kg (apparent Vd). Relatively low, indicating limited extravascular distribution; clinically correlates with low tissue penetration.

ACETAMINOPHEN AND IBUPROFEN

Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).

Bioavailability
KETOROLAC TROMETHAMINE

Oral: 80-100%. Intramuscular: 100%. Ophthalmic: minimal systemic absorption (<0.5% of ocular dose).

ACETAMINOPHEN AND IBUPROFEN

Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.

No specific dosing adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Contraindicated in severe hepatic disease (Child-Pugh C).

ACETAMINOPHEN AND IBUPROFEN

Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.

Pediatric Dosing
KETOROLAC TROMETHAMINE

For patients <16 years: 0.5 mg/kg (maximum 15 mg) single dose IM/IV. Not recommended for repeated dosing or oral use in pediatric patients.

ACETAMINOPHEN AND IBUPROFEN

Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.

Geriatric Dosing
KETOROLAC TROMETHAMINE

For patients ≥65 years: reduce dose by 50% (maximum 60 mg/day IM/IV or 20 mg/day oral). Limit duration to 5 days total therapy.

ACETAMINOPHEN AND IBUPROFEN

Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.

ACETAMINOPHEN AND IBUPROFEN
FDA Black Box Warning

Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.

Warnings/Precautions
KETOROLAC TROMETHAMINE
  • Cardiovascular: Increased risk of thrombotic events, MI, stroke; avoid in patients with recent MI or established cardiovascular disease unless benefit outweighs risk
  • Gastrointestinal: Risk of GI bleeding, ulceration, perforation; use with caution in patients with history of peptic ulcer disease or GI bleeding
  • Renal: Can cause renal toxicity, especially in patients with impaired renal function, dehydration, or concurrent use of diuretics or ACE inhibitors
  • Hematologic: Inhibits platelet aggregation; may prolong bleeding time; use caution in patients with coagulation disorders or on anticoagulants
  • Hypersensitivity: Anaphylactoid reactions may occur; contraindicated in patients with aspirin/NSAID allergy
  • Hepatic: May cause elevations of liver enzymes; rarely, severe hepatic reactions
  • Fluid retention and edema
  • Use in elderly: Increased risk of GI and renal adverse effects
  • Not for use in pediatric patients (except ophthalmic formulations)
  • Not for use during labor and delivery (may inhibit uterine contractions and affect fetal circulation)
ACETAMINOPHEN AND IBUPROFEN

Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.

Contraindications
KETOROLAC TROMETHAMINE
  • Hypersensitivity to ketorolac or other NSAIDs
  • History of asthma, urticaria, or allergic-type reactions after taking aspirin or NSAIDs
  • Active peptic ulcer disease, recent GI bleeding, or perforation
  • History of peptic ulcer disease or GI bleeding
  • Advanced renal disease or patients at risk for renal failure
  • Patients with confirmed or suspected cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding
  • Concurrent use of probenecid (increases ketorolac levels)
  • Concurrent use of aspirin or other NSAIDs (including selective COX-2 inhibitors)
  • Use in patients undergoing coronary artery bypass graft (CABG) surgery
  • Use as prophylactic analgesic before any major surgery
  • Use in labor and delivery (contraindicated due to antiplatelet effect and potential adverse effects on fetal circulation)
  • Use in breastfeeding (due to potential adverse effects on infant)
  • Use in pediatric patients (except ophthalmic drops)
ACETAMINOPHEN AND IBUPROFEN

Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.

Adverse Reactions
KETOROLAC TROMETHAMINE
Data Pending
ACETAMINOPHEN AND IBUPROFEN
Data Pending
Food Interactions
KETOROLAC TROMETHAMINE

Take with food or milk to minimize gastrointestinal irritation. Avoid concomitant use of alcohol as it increases risk of GI bleeding. No specific food interactions; however, high-fat meals may delay absorption but not affect overall efficacy.

ACETAMINOPHEN AND IBUPROFEN

Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.

Lactation Summary
KETOROLAC TROMETHAMINE

Excreted into breast milk; M/P ratio approximately 0.037. Avoid breastfeeding due to potential adverse effects in nursing infants (e.g., gastrointestinal bleeding, renal impairment).

ACETAMINOPHEN AND IBUPROFEN

Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.

Pregnancy Dosing
KETOROLAC TROMETHAMINE

No standard dose adjustment recommended; avoid use in third trimester. In first and second trimesters, use lowest effective dose for shortest duration. Pharmacokinetic changes in pregnancy may increase clearance, but no specific dosing adjustments are established.

ACETAMINOPHEN AND IBUPROFEN

No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.

Maternal Safety Status
KETOROLAC TROMETHAMINE
Category D/X
ACETAMINOPHEN AND IBUPROFEN
Category D/X
Patient Counseling
KETOROLAC TROMETHAMINE

Take this medication exactly as prescribed, usually every 6 to 8 hours, for the shortest time needed (no more than 5 days).,Take with food or a full glass of milk to reduce stomach upset.,Avoid alcohol, aspirin, or other NSAIDs (like ibuprofen, naproxen) while taking this drug.,Stop taking and contact your doctor immediately if you experience signs of bleeding (black tarry stools, vomit that looks like coffee grounds, unusual bruising), chest pain, shortness of breath, weakness on one side of the body, or slurred speech.,Do not use this medicine if you have a history of stomach ulcers, bleeding problems, severe kidney disease, or if you are breastfeeding or in late pregnancy.,Tell your doctor about all medications you take, including blood thinners, steroids, diuretics, and lithium.

ACETAMINOPHEN AND IBUPROFEN

Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.